Para lang sa mga immunocompromised THIRD DOSE SA NATURUKAN NG CHINA VAX

0

INIREKOMENDA ng World Health Organization (WHO) nitong Huwebes ang pagbibigay ng third dose ng COVID-19 vaccine sa mga taong may immunocompromised condition o hindi kayang makapag-develop ng full immunity matapos ang dalawang doses.

“We are now in a position to say that for people with immunocompromised conditions who have been unable to develop full immunity, WHO is supporting a third dose as an extended primary course,” ayon kay WHO Representative to the Philippines Dr. Rabindra Abeyasinghe sa virtual press briefing ni Presidential spokesperson Harry Roque.

“Even if they are less than 60 years old, we will advocate for the third dose,” dagdag na pahayag nito.

Paglilinaw ni Abeyasinghe, ang third dose ay iba mula sa boosters para sa general population.

Sinabi pa niya na inirekomenda ng WHO ang third dose para sa mga taong kabilang sa A2 population, o elderly population, na nakatanggap ng primary vaccination course gamit ang Sinovac o Sinopharm “to potentiate its immunogenicity.”

“Our recommendation now is that in addition to immunocompromised individuals, that we include all individuals who have received primary vaccination course of two doses with Sinovac or Sinopharm to receive a third dose, provided it’s more than three months since the completion of the first two doses,” paglilinaw pa rin ni Abeyasinghe.

“We don’t have a recommendation for the general population,” dagdag na pahayag nito. (CHRISTIAN DALE)

 
"COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by SAKSI NGAYON. Comments are views by saksingayon.com readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of saksingayon.com. While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with SAKSI NGAYON editorial standards, SAKSI NGAYON may not be held liable for any false information posted by readers in this comments section."

Related posts

Leave a Comment